The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies

Current Gene Therapy

Volumn 12, Issue 1, 2012, Pages 33-47

  Penheiter, Alan R ^a   Russell, Stephen J ^a   Carlson, Stephanie K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Gene therapy; Imaging; NIS; Oncolytic virus; PET; Reporter gene; Sodium iodide symporter; SPECT

Indexed keywords

SODIUM IODIDE SYMPORTER; VIRUS VECTOR;

ARTICLE; CELL MIGRATION; CELL THERAPY; GENE THERAPY; HUMAN; NONHUMAN; ONCOLYTIC VIROTHERAPY; POSITRON EMISSION TOMOGRAPHY; REPORTER GENE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIROTHERAPY;

ANIMALIA;

EID: 84858330076     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312799789235     Document Type: Article

References (191)

1. Serganova I, Mayer-Kukuck P, Huang R, Blasberg R. Molecular imaging: reporter gene imaging. Handb Exp Pharmacol [Review] 2008; (185 Pt 2): 167-223.
2. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Voges J, Jacobs AH. Methods to monitor gene therapy with molecular imaging. Methods. Research Support, Non-U.S. Gov't Review. 2009; 48(2): 146-60.
3. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta 1993 Jun 8;1154(1):65-82.
4. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid: official journal of the American Thyroid Association [Review] 2000; 10(4): 321-30.
5. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] 2000; 80(3): 1083-105.
6. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86(7): 3327-35.
7. Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther [Review] 2002; 2(4): 393-402.
8. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) [Research Support, Non-U.S. Gov't Review] 2002; 57(5): 559-74.
9. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43(9): 1188-200.
10. Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review] 2003; 24(1): 48-77.
11. Elisei R, Vivaldi A, Pacini F. Biology and clinical application of the NIS gene. Tumori. [Review] 2003; 89(5): 523-8.
12. Dingli D, Russell SJ, Morris JC. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003; 90(6): 1079-86.
13. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med [Review] 2004; 34(1): 23-31.
14. Baker CH, Morris JC. The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4(3): 167-74.
15. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. [Research Support, Non-U.S. Gov't Review] 2006; 155(4): 495-512.
16. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol [Research Support, Non-U.S. Gov't Review] 2010; 159(4): 761-71.
17. Hingorani M, Spitzweg C, Vassaux G, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets 2010; 10(2): 242-67.
18. Chung JK, Kang JH. Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging 2004; 31: 799-802.
19. Smith VE, Franklyn JA, McCabe CJ. Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol [Research Support, Non-U.S. Gov't Review] 2011; 210(2): 157-63.
20. Czarnocka B. Thyroperoxidase, thyroglobulin, Na(+)/I(-) symporter, pendrin in thyroid autoimmunity. Front Biosci [Research Support, Non-U.S. Gov't Review] 2011; 16: 783-802.
21. Leung AM, Pearce EN, Braverman LE. Perchlorate, iodine and the thyroid. Best Pract Res Clin Endocrinol Metab [Review] 2010; 24(1): 133-41.
22. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010; 15(2): 146-56.
23. Spitzweg C, Morris JC. Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. Mol Cell Endocrinol 2010; 322(1-2): 56-63.
24. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81(3): 1097-142.
25. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 2002; 82(2): 473-502.
26. Pohlenz J, Refetoff S. Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Biochimie 1999; 81(5): 469-76.
27. Bizhanova A, Kopp P. Minireview: The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. Endocrinology 2009; 150(3): 1084-90.
28. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 2007; 3(3): 260-9.
29. Wang ZF, Liu QJ, Liao SQ, et al. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma. Tumori 2011; 97(4): 540-6.
30. Huang H, Shi Y, Lin L, et al. Intracellular iodinated compounds affect sodium iodide symporter expression through TSH-mediated signaling pathways. Mol Med Report 2011; 4(1): 77-80.
31. Harun-Or-Rashid M, Asai M, Sun XY, Hayashi Y, Sakamoto J, Murata Y. Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice. Thyroid Res 2010; 3(1): 3.
32. Serrano-Nascimento C, Calil-Silveira J, Nunes MT. Posttranscriptional regulation of sodium-iodide symporter mRNA expression in the rat thyroid gland by acute iodide administration. Am J Physiol Cell Physiol 2010; 298(4): C893-9.
33. Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010; 95(2): 820-8.
34. Hays MT, Berman M. Pertechnetate distribution in man after intravenous infusion: a compartmental model. J Nucl Med 1977; 18(9): 898-904.
35. Hays MT. Kinetics of the human thyroid trap: a compartmental model. J Nucl Med 1978; 19(7): 789-95.
36. Hays MT. Kinetics of the human thyroid trap: effects of iodide, thyrotropin, and propylthiouracil. J Nucl Med 1979; 20(9): 944-9.
37. Valenta L. Metastatic thyroid carcinoma in man concentrating iodine without organification. J Clin Endocrinol Metab 1966; 26(12): 1317-24.
38. Steinberg M, Cavalieri RR, Choy SH. Uptake of technetium 99-pertechnetate in a primary thyroid carcinoma: need for caution in evaluating nodules. J Clin Endocrinol Metab 1970; 31(1): 81-4.
39. Usher MS, Arzoumanian AY. Thyroid nodule scans made with pertechnetate and iodine may give inconsistent results. J Nucl Med 1971; 12(3): 136-7.
40. Schall GL, Roth JA, Temple R. Differential uptake of 125 I - and 99m TcO 4 - in a histologically unusual metastatic thyroid carcinoma. J Surg Oncol 1973; 5(3): 235-42.
41. Shambaugh GE, Quinn JL, Oyasu R, Freinkel N. Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc 99m and radioactive iodine. Jama 1974; 228(7): 866-9.
42. Hirabayashi S, Koga Y, Kitachara T, Hishida T, Kiga M. Inconsistent images of thyroid nodule scintigrams made with iodine and pertechnetate: case report. J Nucl Med 1975; 16(10): 918.
43. Turner JW, Spencer RP. Thyroid carcinoma presenting as a pertechnetate hot nodule, but without 131I uptake: case report. J Nucl Med 1976; 17(1): 22-3.
44. Reschini E, Ferrari C, Castellani M, et al. The trapping-only nodules of the thyroid gland: prevalence study. Thyroid 2006; 16(8): 757-62.
45. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000; 6(8): 871-8.
46. Josefsson M, Grunditz T, Ohlsson T, Ekblad E. Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand 2002; 175(2): 129-37.
47. Nicola JP, Basquin C, Portulano C, Reyna-Neyra A, Paroder M, Carrasco N. The Na+/I- symporter mediates active iodide uptake in the intestine. Am J Physiol Cell Physiol 2009; 296(4): C654-62.
48. Spitzweg C, Dutton CM, Castro MR, et al. Expression of the sodium iodide symporter in human kidney. Kidney Int 2001; 59(3): 1013-23.
49. Beasley TM, Palmer HE, Nelp WB. Distribution and excretion of technetium in humans. Healthy Physics Pergamon Press 1966; 12: 1425-35.
50. Russo D, Scipioni A, Durante C, et al. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine 2011; 40(1): 35-40.
51. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998; 83(5): 1746-51.
52. Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM. Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol 1999; 141: 382-6.
53. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999; 84(11): 4178-84.
54. MT. 99m Tc-pertechnetate transport in man: absorption after subcutaneous and oral administration; secretion into saliva and gastric juice. J Nucl Med 1973; 14(6): 331-5.
55. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60(13): 3484-92.
56. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379(6564): 458-60.
57. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996; 226(2): 339-45.
58. Pinke LA, Dean DS, Bergert ER, Spitzweg C, Dutton CM, Morris JC. Cloning of the mouse sodium iodide symporter. Thyroid 2001; 11(10): 935-9.
59. Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental 131 therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I-symporter gene. Endocrinology 1997; 138(10): 4493-6.
60. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59(3): 661-8.
61. Nakamoto Y, Saga T, Misaki T, et al. Establishment and characterization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41(11): 1898-904.
62. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60(22): 6526-30.
63. Haberkorn U, Henze M, Altmann A, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42(2): 317-25.
64. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8(20): 1524-31.
65. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002; 13(14): 1723-35.
66. Barton KN, Tyson D, Stricker H, et al. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 2003; 8(3): 508-18.
67. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood 2003; 102(2): 489-96.
68. Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 2003; 10(9): 774-80.
69. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103(5): 1641-6.
70. Faivre J, Clerc J, Gerolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004; 64(21): 8045-51.
71. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9(3): 436-42.
72. Haberkorn U, Beuter P, Kubler W, et al. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. J Nucl Med 2004; 45(5): 827-33.
73. Kang JH, Chung JK, Lee YJ, et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 2004; 45(9): 1571-6.
74. Marsee DK, Shen DH, MacDonald LR, et al. Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed tomography. Cancer Gene Ther 2004; 11(2): 121-7.
75. Niu G, Gaut AW, Ponto LL, et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med 2004; 45(3): 445-9.
76. Shen DH, Marsee DK, Schaap J, et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 2004; 11(2): 161-9.
77. Shin JH, Chung JK, Kang JH, et al. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk. Eur J Nucl Med Mol Imaging 2004; 31(3): 425-32.
78. So MK, Kang JH, Chung JK, et al. In vivo imaging of retinoic acid receptor activity using a sodium/iodide symporter and luciferase dual imaging reporter gene. Mol Imaging 2004; 3(3): 163-71.
79. Yang HS, Lee H, Kim SJ et al. Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats. Eur J Nucl Med Mol Imaging 2004; 31(9): 1304-11.
80. Che J, Doubrovin M, Serganova I, Ageyeva L, Zanzonico P, Blasberg R. hNIS-IRES-eGFP dual reporter gene imaging. Mol Imaging 2005; 4(2): 128-36.
81. Dingli D, Peng KW, Harvey ME, et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 2005; 337(1): 22-9.
82. Dwyer RM, Bergert ER, O'Connor M K, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11(4): 1483-9.
83. Lee KH, Kim HK, Paik JY, et al. Accuracy of myocardial sodium/iodide symporter gene expression imaging with radioiodide: evaluation with a dual-gene adenovirus vector. J Nucl Med 2005; 46(4): 652-7.
84. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 2006; 8(6): 324-32.
85. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006; 47(5): 854-62.
86. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 2006; 17(6): 661-8.
87. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006; 13(1): 60-6.
88. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006; 12(6): 1868-75.
89. Mitrofanova E, Unfer R, Vahanian N, Link C. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy. Gene Ther 2006; 13(13): 1052-6.
90. Chen C-Y, Chang P-J, Changlai S-P, Pan L-K. Effective Half Life of Iodine for Five Thyroidectomy Patients Using an in vivo Gamma Camera Approach. J Radiat Res 2007; 48(6): 485-93.
91. Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110(7): 2342-50.
92. Merron A, Peerlinck I, Martin-Duque P, et al. SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 2007; 14(24): 1731-8.
93. Schipper ML, Riese CG, Seitz S, et al. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo. Eur J Nucl Med Mol Imaging. 2007; 34(5): 638-50.
94. Siddiqui F, Barton KN, Stricker HJ, et al. Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther 2007; 18(4): 312-22.
95. Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007; 18(10): 916-24.
96. Willhauck MJ, Sharif Samani BR, Gildehaus FJ, et al. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2007; 92(11): 4451-8.
97. Barton KN, Stricker H, Brown SL, et al. Non-Invasive, Quantitative Imaging of Adenovirus-Mediated Gene Expression in Humans with Prostate Cancer. American Society of Gene Therapy 11th Annual Meeting; May 30, 2008; Boston, Massachusetts: American Society of Gene Therapy; 2008.
98. Herve J, Cunha AS, Liu B, et al. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther 2008; 19(9): 915-26.
99. Kim SH, Chung HK, Kang JH, et al. Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther 2008 Sep; 19(9): 951-7.
100. Park SY, Kwak W, Tapha N, et al. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. J Nucl Med 2008; 49: 1480-8.
101. Willhauck MJ, Sharif Samani BR, Klutz K, et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15(3): 214-23.
102. Yeom CJ, Chung JK, Kang JH, et al. Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med 2008; 49(9): 1489-97.
103. Carlson SK, Classic KL, Hadac EM, et al. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol 2009; 192(1): 279-87.
104. Msaouel P, Iankov ID, Allen C, et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17(12): 2041-8.
105. Pham L, Nakamura T, Gabriela Rosales A, et al. Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. J Gene Med 2009; 11(3): 197-206.
106. Merron A, Baril P, Martin-Duque P, et al. Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging 2010; 37(7): 1377-85.
107. Endo T, Shimura H, Saito T, Onaya T. Cloning of malignantly transformed rat thyroid (FRTL) cells with thyrotropin receptors and their growth inhibition by 3',5'-cyclic adenosine monophosphate. Endocrinology 1990; 126(3): 1492-7.
108. Dingli D, Bergert ER, Bajzer Z, O'Connor M K, Russell SJ, Morris JC. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 2004; 325(1): 157-66.
109. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid: official journal of the American Thyroid Association 2004; 14(6): 424-34.
110. Miyagawa M, Beyer M, Wagner B, et al. Cardiac reporter gene imaging using the human sodium/iodide symporter gene. Cardiovasc Res 2005; 65(1): 195-202.
111. Rao VP, Miyagi N, Ricci D, et al. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. Transplantation 2007; 84(12): 1662-6.
112. Ricci D, Mennander AA, Pham LD, et al. Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. Eur J Cardiothorac Surg 2008; 33(1): 32-9.
113. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28(7): 326-33.
114. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy 2007; 15(4): 651-9.
115. Stanford MM, Bell JC, Vaha-Koskela MJ. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2010; 21(2-3): 177-83.
116. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev 2010; 21(2-3): 85-9.
117. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18(2): 243-50.
118. Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther 2011 Apr; 19(4): 627-8.
119. Barton KN, Freytag SO, Nurushev T, et al. A model for optimizing adenoviral delivery in human cancer gene therapy trials. Hum Gene Ther 2007; 18(6): 562-72.
120. Barton KN, Stricker H, Brown SL, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16(10): 1761-9.
121. Barton KN, Stricker H, Elshaikh MA, et al. Feasibility of Adenovirus-Mediated hNIS Gene Transfer and (131)I Radioiodine Therapy as a Definitive Treatment for Localized Prostate Cancer. Mol Ther 2011; 19(7): 1353-9.
122. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther 2011.
123. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009; 11(1): 43-53.
124. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17(8): 550-8.
125. Peerlinck I, Merron A, Baril P, et al. Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res 2009; 15(21): 6595-601.
126. Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris JC. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res 2009; 11(4): R53.
127. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 2010; 17(11): 1325-32.
128. Haddad D, Chen NG, Zhang Q, et al. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med 2011; 9: 36.
129. Terrovitis J, Kwok KF, Lautamaki R, et al. Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. J Am Coll Cardiol 2008; 52(20): 1652-60.
130. Welling MM, Duijvestein M, Signore A, van der Weerd L. In vivo biodistribution of stem cells using molecular nuclear medicine imaging. J Cell Physiol 2011; 226(6): 1444-52.
131. Higuchi T, Anton M, Saraste A, et al. Reporter gene PET for monitoring survival of transplanted endothelial progenitor cells in the rat heart after pretreatment with VEGF and atorvastatin. J Nucl Med 2009; 50(11): 1881-6.
132. Seo JH, Jeon YH, Lee YJ, et al. Trafficking macrophage migration using reporter gene imaging with human sodium iodide symporter in animal models of inflammation. J Nucl Med 2010; 51(10): 1637-43.
133. Bloomfield PM, Rajeswaran S, Spinks TJ, et al. The design and physical characteristic of a small animal positron emission tomograph. Phys Med Biol 1995; 40(6): 1105.
134. Schafers KP, Reader AJ, Kriens M, Knoess C, Schober O, Schafers M. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med 2005; 46(6): 996-1004.
135. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002; 46(1): 35-47.
136. Forrer F, Valkema R, Bernard B, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging 2006; 33(10): 1214-7.
137. Seo Y, Gao DW, Hasegawa BH, Dae MW, Franc BL. Rodent brain imaging with SPECT/CT. Med Phys 2007; 34(4): 1217-20.
138. Beekman F, van der Have F. The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur J Nucl Med Mol Imaging 2007; 34(2): 151-61.
139. Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med 2008; 49(10): 1651-63.
140. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging. J Nucl Med 2009; 50(4): 599-605.
141. Magota K, Kubo N, Kuge Y, Nishijima K, Zhao S, Tamaki N. Performance characterization of the Inveon preclinical small-animal PET/SPECT/CT system for multimodality imaging. Eur J Nucl Med Mol Imaging 2011; 38(4): 742-52.
142. Branderhorst W, Vastenhouw B, van der Have F, Blezer EL, Bleeker WK, Beekman FJ. Targeted multi-pinhole SPECT. Eur J Nucl Med Mol Imaging 2011; 38(3): 552-61.
143. Cheng D, Wang Y, Liu X, et al. Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice. Bioconjug Chem 2010; 21(8): 1565-70.
144. King MA, Pretorius PH, Farncombe T, Beekman FJ. Introduction to the physics of molecular imaging with radioactive tracers in small animals. J Cell Biochem Suppl 2002; 39: 221-30.
145. Ljunberg M, Sjogreen K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for I-131 using Monte Carlo simulation. J Nucl Med 2002; 43: 1101-9.
146. King M, Farncombe T. An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer Biother Radiopharm 2003; 18(2): 181-90.
147. Chatziloannou AF. Instrumentation for molecular imaging in preclinical research. Proc Am Thorac Soc 2005; 2: 533-6.
148. Rowland DJ, Cherry SR. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 2008; 38(3): 209-22.
149. Kagadis GC, Loudos G, Katsanos K, Langer SG, Nikiforidis GC. In vivo small animal imaging: current status and future prospects. Med Phys 2010; 37(12): 6421-42.
150. Niu G, Krager KJ, Graham MM, Hichwa RD, Domann FE. Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter. Eur J Nucl Med Mol Imaging 2005; 32(5): 534-40.
151. Biersack HJ, Freeman LM. Clinical nuclear medicine. Berlin; New York: Springer; 2007.
152. Jauregui-Osoro M, Sunassee K, Weeks AJ, et al. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010; 37(11): 2108-16.
153. Youn H, Jeong JM, Chung JK. A new PET probe, (18)F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur J Nucl Med Mol Imaging 2010; 37(11): 2105-7.
154. Vadysirisack DD, Shen DH, Jhiang SM. Correlation of Na+/I-symporter expression and activity: implications of Na+/I-symporter as an imaging reporter gene. J Nucl Med 2006; 47(1): 182-90.
155. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 2000; 97(6): 2785-90.
156. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2(1-2): 118-38.
157. Luker GD, Luker KE. Optical imaging: current applications and future directions. J Nucl Med 2008; 49(1): 1-4.
158. He Z, Evelhoch JL, Mohammad RM, Adsay NV, Pettit GR, Vaitkevicius VK, et al. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 2000; 21(1): 69-76.
159. Wunderbaldinger P, Bogdanov A, Weissleder R. New approaches for imaging in gene therapy. Eur J Radiol 2000; 34(3): 156-65.
160. Gilad AA, Ziv K, McMahon MT, van Zijl PC, Neeman M, Bulte JW. MRI reporter genes. J Nucl Med 2008; 49(12): 1905-8.
161. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002; 16(4): 336-51.
162. Neve KA, Cox BA, Henningsen RA, Spanoyannis A, Neve RL. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol 1991; 39(6): 733-9.
163. Kang JH, Lee DS, Paeng JC, et al. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression. J Nucl Med 2005; 46(3): 479-83.
164. Kemerink GJ, Visser MG, Franssen R, et al. Effect of the positron range of 18F, 68Ga and 124I on PET/CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging 2011; 38(5): 940-8.
165. Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging 2011; 38 Suppl 1: S10-8.
166. Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of 124I with PET/ CT in pretherapy lesion dosimetry Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging 2011; 55(1): 21-43.
167. Liang Q, Satyamurthy N, Barrio JR, et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 2001; 8(19): 1490-8.
168. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999; 6(5): 785-91.
169. Ogawa O, Umegaki H, Ishiwata K, et al. In vivo imaging of adenovirus-mediated over-expression of dopamine D2 receptors in rat striatum by positron emission tomography. Neuroreport 2000; 11(4): 743-8.
170. Umegaki H, Ishiwata K, Ogawa O, et al. In vivo assessment of adenoviral vector-mediated gene expression of dopamine D(2) receptors in the rat striatum by positron emission tomography. Synapse 2002; 43(3): 195-200.
171. Herschman HR. Noninvasive imaging of reporter gene expression in living subjects. Adv Cancer Res 2004; 92: 29-80.
172. Saito Y, Price RW, Rottenberg DA, et al. Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug. Science 1982; 217(4565): 1151-3.
173. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995; 55(24): 6126-32.
174. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56(18): 4087-95.
175. Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002; 43(8): 1072-83.
176. Min JJ, Iyer M, Gambhir SS. Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging 2003; 30(11): 1547-60.
177. Miyagawa T, Gogiberidze G, Serganova I, et al. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med 2008; 49(4): 637-48.
178. Ruggiero A, Brader P, Serganova I, et al. Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleoside probes. Mol Imaging 2010; 9(1): 47-58.
179. Brust P, Haubner R, Friedrich A, et al. Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur J Nucl Med 2001; 28(6): 721-9.
180. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007; 15(9): 1600-6.
181. Chaudhuri TR, Rogers BE, Buchsbaum DJ, Mountz JM, Zinn KR. A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol 2001; 83(2): 432-8.
182. Zinn KR, Chaudhuri TR, Krasnykh VN, et al. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 2002; 223(2): 417-25.
183. Zinn KR, Chaudhuri TR. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med Mol Imaging 2002; 29(3): 388-99.
184. Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J Nucl Med 2005; 46(11): 1889-97.
185. Schellingerhout D. Molecular imaging of novel cell- and viral-based therapies. Neuroimaging Clin N Am 2006; 16(4): 655-79, ix.
186. Cotugno G, Aurilio M, Annunziata P, et al. Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography. Hum Gene Ther 2011; 22(2):189-96.
187. Moroz MA, Serganova I, Zanzonico P, et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 2007; 48(5): 827-36.
188. Brader P, Kelly KJ, Chen N, et al. Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene. Clin Cancer Res 2009; 15(11): 3791-801.
189. Altmann A, Kissel M, Zitzmann S, et al. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 2003; 44(6): 973-80.
190. Anton M, Wagner B, Haubner R, et al. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med 2004; 6(1): 119-26.
191. Weeks AJ, Jauregui-Osoro M, Cleij M, Blower JE, Ballinger JR, Blower PJ. Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Commun 2011; 32(2): 98-105.